Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Velusetrag - Theravance Biopharma

Drug Profile

Velusetrag - Theravance Biopharma

Alternative Names: TD-5108

Latest Information Update: 01 Feb 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Theravance
  • Developer Alfa Wassermann SpA; Theravance Biopharma
  • Class Azabicyclo compounds; Gastrokinetics; Small molecules
  • Mechanism of Action Serotonin 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gastroparesis
  • Discontinued Alzheimer's disease; Constipation

Most Recent Events

  • 01 Feb 2018 Velusetrag is still at phase II development stage for Gastroparesis in USA, Czech Republic and Poland (PO) (Theravance Biopharma pipeline, February 2018)
  • 03 Aug 2017 Adverse events and efficacy data from a phase IIb trial in Gastroparesis released by Theravance
  • 01 Jul 2017 Theravance completes a phase IIb trial for Gastroparesis in USA, Czech republic and Poland (NCT02267525)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top